PRESTIGE CONSUMER HEALTHCARE INC. Acquisitions, Net of Cash Acquired
PRESTIGE CONSUMER HEALTHCARE INC. (PBH) reported Acquisitions, Net of Cash Acquired of $1.04 billion for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired · last filed 2026-08-06
- PRESTIGE CONSUMER HEALTHCARE INC. payments to acquire businesses, net of cash acquired for the quarter ending 2026-06-30 was $1.04B.
- PRESTIGE CONSUMER HEALTHCARE INC. payments to acquire businesses, net of cash acquired for the quarter ending 2026-03-31 was -$1.80M.
- PRESTIGE CONSUMER HEALTHCARE INC. payments to acquire businesses, net of cash acquired for the quarter ending 2025-06-30 was $0.00.
- PRESTIGE CONSUMER HEALTHCARE INC. payments to acquire businesses, net of cash acquired for the quarter ending 2025-03-31 was $0.00.
- PRESTIGE CONSUMER HEALTHCARE INC. payments to acquire businesses, net of cash acquired for fiscal 2026 was $123.74M, a 1399.83% increase from fiscal 2025.
- PRESTIGE CONSUMER HEALTHCARE INC. payments to acquire businesses, net of cash acquired for fiscal 2025 was $8.25M, a 21.88% decline from fiscal 2024.
- PRESTIGE CONSUMER HEALTHCARE INC. payments to acquire businesses, net of cash acquired for fiscal 2024 was $10.56M.
- PRESTIGE CONSUMER HEALTHCARE INC. payments to acquire businesses, net of cash acquired for fiscal 2023 was $0.00, a 100.00% decline from fiscal 2022.
| Period end | Payments to Acquire Businesses, Net of Cash Acquired 3 month | Payments to Acquire Businesses, Net of Cash Acquired 6 month | Payments to Acquire Businesses, Net of Cash Acquired 6 month as first filed | Payments to Acquire Businesses, Net of Cash Acquired 9 month | Payments to Acquire Businesses, Net of Cash Acquired 9 month as first filed | Payments to Acquire Businesses, Net of Cash Acquired 12 month | Payments to Acquire Businesses, Net of Cash Acquired 12 month as first filed |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | $1.04B 10-Q · filed 2026-08-06 | $1.04B derived: sum of 2 quarters · filed 2026-08-06 | |||||
| 2026-03-31 | -$1.80M derived: 10-K 12 month − 10-Q 9 month · filed 2026-05-14 | $123.74M 10-K · filed 2026-05-14 | |||||
| 2025-12-31 | $125.53M 10-Q · filed 2026-02-05 | ||||||
| 2025-06-30 | $0.00 10-Q · filed 2026-08-06 | $0.00 derived: sum of 2 quarters · filed 2026-08-06 | |||||
| 2025-03-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-05-14 | $8.25M 10-K · filed 2026-05-14 | |||||
| 2024-12-31 | $8.25M 10-Q · filed 2026-02-05 | ||||||
| 2024-03-31 | $10.56M 10-K · filed 2026-05-14 | ||||||
| 2023-03-31 | $0.00 10-K · filed 2023-05-05 | ||||||
| 2022-03-31 | $247.05M 10-K · filed 2023-05-05 | ||||||
| 2021-03-31 | $0.00 10-K · filed 2023-05-05 | ||||||
| 2020-03-31 | $2.76M 10-K · filed 2022-05-06 | ||||||
| 2018-03-31 | $0.00 10-K · filed 2018-05-10 | ||||||
| 2017-03-31 | $0.00 10-K · filed 2018-05-10 | ||||||
| 2016-03-31 | $226.98M 10-K · filed 2018-05-10 | ||||||
| 2015-06-30 | $0.00 10-Q · filed 2015-08-06 | -$77.99M derived: sum of 2 quarters · filed 2017-05-17 | -$77.99M derived: sum of 3 quarters · filed 2017-05-17 | -$77.99M derived: sum of 4 quarters · filed 2017-05-17 | |||
| 2015-03-31 | -$77.99M derived: 10-K 12 month − 10-Q 9 month · filed 2017-05-17 | -$77.99M derived: sum of 2 quarters · filed 2017-05-17 | -$77.99M derived: sum of 3 quarters · filed 2017-05-17 | $0.00 10-K · filed 2017-05-17 | $749.67M 10-K · filed 2015-05-14 | ||
| 2014-12-31 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2015-02-05 | $0.00 derived: sum of 2 quarters · filed 2015-11-05 | $77.99M 10-Q · filed 2015-02-05 | $77.99M derived: sum of 4 quarters · filed 2015-11-05 | |||
| 2014-09-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2015-11-05 | $77.99M 10-Q · filed 2015-11-05 | $77.99M derived: sum of 3 quarters · filed 2015-11-05 | $77.99M derived: sum of 4 quarters · filed 2015-11-05 | |||
| 2014-06-30 | $77.99M 10-Q · filed 2015-08-06 | $77.99M derived: sum of 2 quarters · filed 2015-08-06 | $77.99M derived: sum of 3 quarters · filed 2015-08-06 | $77.99M derived: sum of 4 quarters · filed 2015-08-06 | |||
| 2014-03-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2015-05-14 | $0.00 derived: sum of 2 quarters · filed 2015-05-14 | $0.00 derived: sum of 3 quarters · filed 2015-05-14 | $0.00 10-K · filed 2015-05-14 | $55.22M 10-K · filed 2014-05-19 | ||
| 2013-12-31 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2015-02-05 | $0.00 derived: sum of 2 quarters · filed 2015-02-05 | $0.00 10-Q · filed 2015-02-05 | $55.22M 10-Q · filed 2014-02-07 | $0.00 derived: sum of 4 quarters · filed 2015-05-14 | ||
| 2013-09-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2014-11-06 | $0.00 10-Q · filed 2014-11-06 | $55.22M 10-Q · filed 2013-11-07 | $0.00 derived: sum of 3 quarters · filed 2015-05-14 | $0.00 derived: sum of 4 quarters · filed 2015-05-14 | ||
| 2013-06-30 | $0.00 10-Q · filed 2014-08-07 | $0.00 derived: sum of 2 quarters · filed 2015-05-14 | $0.00 derived: sum of 3 quarters · filed 2015-05-14 | ||||
| 2013-03-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2015-05-14 | $0.00 derived: sum of 2 quarters · filed 2015-05-14 | $0.00 10-K · filed 2015-05-14 | ||||
| 2012-12-31 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2014-02-07 | $0.00 10-Q · filed 2014-02-07 | |||||
| 2012-09-30 | $0.00 10-Q · filed 2013-11-07 | ||||||
| 2012-03-31 | $662.80M derived: 10-K 12 month − 10-Q 9 month · filed 2014-05-19 | $662.80M 10-K · filed 2014-05-19 | |||||
| 2011-12-31 | $0.00 10-Q · filed 2012-02-09 | ||||||
| 2010-12-31 | $202.04M 10-Q · filed 2012-02-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 | |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |